Showing 109 news articles about PrEP science

Filters Content type: Editors' picks Topic: PrEP science

Research, news and information on the effectiveness of oral pre-exposure prophylaxis (PrEP) and its impact on HIV epidemics, as well as clinical issues for PrEP users.

PrEP science

Large Global Analysis Finds Tenofovir Disoproxil Fumarate PrEP Safe and Effective, Even With Imperfect Adherence

Editor's pick
TheBodyPro
6 May 2024
PrEP science

Kidney Function Not Improved in Patients Who Switch to TAF-Based PrEP

Editor's pick
Infectious Disease Advisor
6 February 2024
PrEP science

Resistance Mutation Associated With PrEP Use in People Newly Diagnosed With HIV in New York City

Editor's pick
TheBodyPro
5 January 2024
PrEP science

On-Demand Versus Daily PrEP May Mitigate TDF’s Effect on Kidneys, Reports French Study

Editor's pick
TheBodyPro
28 December 2023
Resistance

History of PrEP Use Linked to M184I/V Mutation at HIV Diagnosis

Editor's pick
Infectious Disease Advisor
22 December 2023
Antibody-based prevention

Oral tenofovir/FTC increases clearance of bNAb VRC01: implications for future research

Editor's pick
i-Base
4 December 2023
PrEP science

Cabotegravir Safe and Effective for Pre-Exposure Prophylaxis in Transgender Women, Global Study Finds

Editor's pick
TheBodyPro
30 October 2023
The search for an HIV prevention vaccine

A trial is underway that could be ‘the last roll of the dice’ for an HIV vaccine this decade

Editor's pick
CNN
28 August 2023
PrEP science

Adherence Support Needed for MSM Choosing On-Demand PrEP, West African Study Reports

Editor's pick
TheBodyPro
5 June 2023
PrEP science

Oral PrEP Is Effective for Women, but Only if They Take it Consistently

Editor's pick
POZ
23 May 2023
The search for an HIV prevention vaccine

It’s Time to End AIDS: Why EU Should Fund Search for HIV Vaccine

Editor's pick
Health Policy Watch
19 May 2023
Injectable & long-acting PrEP

Large Benefit With Long-Acting PrEP in Black People, but Some HIV Risk Persists

Editor's pick
MedPage Today
22 February 2023
PrEP programmes & uptake

Preexposure Prophylaxis Gives Good Results in Latin America

Editor's pick
Medscape (requires free registration)
23 January 2023
PrEP science

For Patients Taking PrEP, Poor Adherence Drives HIV Seroconversions

Editor's pick
Physician's Weekly
5 October 2022
New & experimental HIV treatments

Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection

Editor's pick
Merck press release
20 September 2022
PrEP science

On-Demand PrEP Works as Well as Daily Pills

Editor's pick
POZ
13 July 2022
PrEP policies & guidelines

PrEP Can Be Cost-Effective in Sub-Saharan Africa

Editor's pick
Contagion Live
16 May 2022
PrEP science

Long-acting doravirine implants as PrEP to prevent vaginal HIV transmission in mouse study

Editor's pick
i-Base
24 February 2022
Drug interactions & pharmacokinetics

No Interactions Between Hormone Therapy and PrEP in Transgender Women or Men

Editor's pick
NATAP
24 February 2022
PrEP science

Landscape report launched on novel technologies for the prevention of HIV, STIs, and unwanted pregnancy

Editor's pick
Unitaid
10 December 2021
Adherence

Digital pill tracks HIV prevention pill adherence with 98 percent accuracy

Editor's pick
European Pharmaceutical Review
9 December 2021
Pharmaceutical industry

Merck pauses 2 more trials of backbone HIV drug over red flag, raising doubts about multi-pronged R&D strategy

Editor's pick
FierceBiotech
7 December 2021
PrEP science

Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis (PrEP) of HIV-1 infection

Editor's pick
BusinessWire
7 December 2021
PrEP science

Kidney Toxicity Rare With Daily or On-Demand (As-Needed) PrEP

Editor's pick
NATAP
31 October 2021